Budiey
Merz Aesthetics announced today that Ultherapy® is celebrating the milestone achievement of providing one million treatments globally. Since its global launch in 2008, the non-invasive ultrasound device has become a game-changer in physician offices worldwide by using the body’s own regenerative response to gently and naturally stimulate collagen growth. This revolutionary treatment is the only U.S FDA-cleared non-invasive skin-lift for neck, under the chin and on the eyebrow. Now Authentic Ultherapy™ is also U.S FDA-cleared to improve the appearance of lines and wrinkles on the décolletage.
“Ultherapy® is frequently requested in my office because it’s non-invasive, naturally stimulates collagen growth, and provides visible results. Because of this, the treatment has become a favorite among my patients, so it is no surprise that it has reached such a remarkable milestone,” states Dr Cheok Jia Rhong, Aesthetic Medicine Practitioner (LCP Holder).
“Not only does the treatment deliver these incredible benefits, it also requires little to no downtime, allowing those treated with Ultherapy® to quickly get back to their everyday routines.”
Making the treatment even more popular among physicians, Ultherapy®’s proprietary DeepSEE™ ultrasound imaging allows physicians to see the layers of tissue targeted during the treatment to ensure energy is deposited where it will be most beneficial. This unique technology is supported by more than 50 clinical studies, more than 60 published, peer reviewed papers, and over 100 patents worldwide.
“We’re extremely proud to be celebrating this milestone of treating one million patients with Ultherapy® on a global scale,” said Philip Burchard, Chief Executive Officer, Merz Pharma. “Ultherapy® continues to lead in the category due to its breakthrough, award-winning innovation, our dedicated physicians, and consistent patient satisfaction. We look forward to celebrating the next million treatments.”
Merz Malaysia will be celebrating the physicians who played a role in the success of Ultherapy’s® 1 Million Treatment achievement worldwide.
For full product and safety information, including possible mild side effects of Ultherapy®, please refer to the Ulthera® System Instructions for Use.
About Merz Pharma Group
With approximately 3,000 employees and 34 subsidiaries, Merz is a leading global provider in the fields of Aesthetics and Neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. Complementing its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy to treat neurologically induced movement disorders. OTC medicines, dietary supplements and skincare products round off the offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2015/16, the Merz Pharma Group generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.
